Long-term HPV type-specific risks of high-grade cervical intraepithelial lesions: A 14-year follow-up of a randomized primary HPV screening trial

International Journal of Cancer

Volumn 136, Issue 5, 2015, Pages 1171-1180

  Smelov, Vitaly ^a   Elfström, K Miriam ^a   Johansson, Anna L V ^a   Eklund, Carina ^a   Naucler, Pontus ^a,b   Arnheim Dahlström, Lisen ^a   Dillner, Joakim ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cervical cancer screening; HPV infections; HPV testing; HSIL

Indexed keywords

ADULT; ARTICLE; CANCER GRADING; CANCER INCIDENCE; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 51; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 56; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN PAPILLOMAVIRUS TYPE 68; MAJOR CLINICAL STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS; CERVICAL INTRAEPITHELIAL NEOPLASIA; DOUBLE BLIND PROCEDURE; GENETICS; GENOTYPE; INCIDENCE; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTIONS; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SWEDEN; TIME; UTERINE CERVICAL NEOPLASMS; VIROLOGY;

VIRUS DNA;

ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; DNA, VIRAL; DOUBLE-BLIND METHOD; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INCIDENCE; NEOPLASM GRADING; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SWEDEN; TIME FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84918772435     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29085     Document Type: Article

References (37)

1. Forman D, De Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012;30 Suppl 5:F12-23.
2. Bray F, Sankila R, Ferlay J, et al. Estimates of cancer incidence and mortality in Europe in 1995. Eur J Cancer 2002;38:99-166.
3. Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810-9.
4. Mayrand MH, Duarte-Franco E, Rodrigues I, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007;357:1579-88.
5. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-9.
6. Kotaniemi-Talonen L, Nieminen P, Anttila A, et al. Routine cervical screening with primary HPV testing and cytology triage protocol in a randomised setting. Br J Cancer 2005;93:862-7.
7. Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44, 102 women. Int J Cancer 2004;110:94-101.
8. Naucler P, Ryd W, Törnberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357:1589-97.
9. Ronco G, Giorgi-Rossi P, Carozzi F, et al. New Technologies for Cervical Cancer screening Working Group. Human papillomavirus testing and liquid-based cytology in primary screening of women younger than 35 years: results at recruitment for a randomised controlled trial. Lancet Oncol 2006;7:547-55.
10. Ronco G, Dillner J, Elfström KM, et al. Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet 2014;383:524-32.
11. Naucler P, Ryd W, Törnberg S, et al. HPV typespecific risks of high-grade CIN during 4 years of follow-up: a population-based prospective study. Br J Cancer 2007;97:129-32.
12. Sundström K, Eloranta S, Sparén P, et al. Prospective study of human papillomavirus (HPV) types, HPV persistence, and risk of squamous cell carcinoma of the cervix. Cancer Epidemiol Biomarkers Prev 2010;19:2469-78.
13. Dahlström LA, Ylitalo N, Sundström K, et al. Prospective study of human papillomavirus and risk of cervical adenocarcinoma. Int J Cancer 2010;127:1923-30.
14. Canfell K, Chesson H, Kulasingam SL, et al. Modeling preventative strategies against human papillomavirus-related disease in developed countries. Vaccine 2012;30 Suppl 5:F157-67.
15. Elfgren K, Rylander E, Rådberg T, et al. Colposcopic and histopathologic evaluation of women participating in population-based screening for human papillomavirus deoxyribonucleic acid persistence. Am J Obstet Gynecol 2005;193:650-7.
16. Elfstrom KM, Smelov V, Johansson AL, et al. Long term duration of protective effect for HPV negative women: follow-up of primary HPV screening randomised controlled trial. BMJ 2014;348:g130.
17. Forslund O, Antonsson A, Edlund K, et al. Populationbased type-specific prevalence of high-risk human papillomavirus infection in middle-aged Swedish women. J Med Virol 2002;66:535-41.
18. Jacobs MV, Snijders PJ, Voorhorst FJ, et al. Reliable high risk HPV DNA testing by polymerase chain reaction: an intermethod and intramethod comparison. J Clin Pathol 1999;52:498-503.
19. Wahlstrom C, Iftner T, Dillner J, et al. Populationbased study of screening test performance indices of three human papillomavirus DNA tests. J Med Virol 2007;79:1169-75.
20. Söderlund-Strand A, Carlson J, Dillner J. Modified general primer PCR system for sensitive detection of multiple types of oncogenic human papillomavirus. J Clin Microbiol 2009 Mar; 47:541-6.
21. Schmitt M, Bravo IG, Snijders PJ, et al. Beadbased multiplex genotyping of human papillomaviruses. J Clin Microbiol 2006;44:504-12.
22. Eklund C, Zhou T, Dillner J, et al. Global proficiency study of human papillomavirus genotyping. J Clin Microbiol 2010;48:4147-55.
23. Eklund C, Forslund O, Wallin KL, et al. The 2010 global proficiency study of human papillomavirus genotyping in vaccinology. J Clin Microbiol 2012;50:2289-98.
24. Rothman KJ, Greenland S. Modern Epidemiology, 2nd ed. Philadelphia, PA: Lippincott Williams and Wilkins, 1998.
25. Elfström KM, Smelov V, Johansson AL, et al. Long-term HPV type-specific risks for ASCUS and LSIL: a 14-year follow-up of a randomized primary HPV screening trial. Int J Cancer 2014. doi: 10.1002/ijc.28984 [Epub ahead of print].
26. Bouvard V, Baan R, Straif K, Grosse Y, et al. A review of human carcinogens-part B: biological agents. Lancet Oncol 2009;10:321-2.
27. Bzhalava D1, Guan P, Franceschi S, et al. A systematic review of the prevalence of mucosal and cutaneous human papillomavirus types. Virology 2013;445:224-31.
28. Litjens RJ, Van De Vijver KK, Hopman AH, et al. The majority of metachronous CIN1 and CIN3 lesions are caused by different human papillomavirus genotypes, indicating that the presence of CIN1 seems not to determine the risk for subsequent detection of CIN3. Hum Pathol 2014;45:221-6.
29. Dillner J, Rebolj M, Birembaut P, et al. Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study. BMJ 2008;337:a1754.
30. Sargent A, Bailey A, Almonte M, et al. Prevalence of type-specific HPV infection by age and grade of cervical cytology: data from the ARTISTIC trial. Br J Cancer 2008;98:1704-9.
31. Leinonen M, Kotaniemi-Talonen L, Anttila A, et al. Prevalence of oncogenic human papillomavirus infection in an organised screening population in Finland. Int J Cancer 2008;123:1344-9.
32. Coupé VM, Berkhof J, Bulkmans NW, et al. Agedependent prevalence of 14 high-risk HPV types in the Netherlands: implications for prophylactic vaccination and screening. Br J Cancer 2008;98:646-51.
33. Rijkaart DC, Berkhof J, Rozendaal L, et al. Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trial. Lancet Oncol 2012;13:78-88.
34. Carozzi F, Gillio-Tos A, Confortini M, et al. Risk of high-grade cervical intraepithelial neoplasia during follow-up in HPV-34.positive women according to baseline p16-INK4A results: a prospective analysis of a nested substudy of the NTCC randomised controlled trial. Lancet Oncol 2013;14:168-76.
35. Ogilvie GS, Van Niekerk DJ, Krajden M, et al. A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial). BMC Cancer 2010;10:111.
36. Schiffman M, Glass AG, Wentzensen N, et al. A long-term prospective study of type-specific human papillomavirus infection and risk of cervical neoplasia among 20, 000 women in the Portland Kaiser Cohort Study. Cancer Epidemiol Biomarkers Prev 2011;20:1398-409.
37. Peng J, Gao L, Guo J, et al. Type-specific detection of 30 oncogenic human papillomaviruses by genotyping both E6 and L1 genes. J Clin Microbiol 2013;51:402-8.